Bispebjerg University Hospital
Copenhagen, 2200, Denmark
NCT Number: NCT05845177
This study is a nationwide cross-sectional survey on pain and satisfaction after total hip arthroplasty (THA). Please find the full protocol uploaded on ClinicalTrials.gov
Looking for future studies?
Notify Me18 year–99 year
All sexes
Observational
Copenhagen, 2200, Denmark
The study is registered at the Capitol region of Denmark's regional research listing (Pactius) with identifier P-2022-933, approved 23 December 2022. The resulting paper will be reported according to the CROSS checklist for standardised reporting of survey studies. Wherever needed, a trained linguist translated questions from English to Danish and vice versa. The Danish and an English version of the questionnaire will be available in the final publication.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
Other names: Primary Total Hip Replacement
Time frame: 12-15 months postoperatively
The main outcome is the number of patients with moderate or severe persistent postsurgical pain in the operated hip, defined as patients with a numerical rating scale (NRS) score higher than 3. The NRS score was dichotomised for the primary outcome because this is more intuitively understood by patients and clinicians. This outcome will be reported as percentage of all patients with 95% confidence interval, which is calculated with assumed binomial distribution as p ± 1.96 √( (p (1 - p) ) / n)
Time frame: 12-15 months postoperatively
Reported as n (%) for each response option. The 1st question assesses overall satisfaction with surgery and have been translated directly from the questionnaire used by the Swedish Arthroplasty Register.
Time frame: 12-15 months postoperatively
Reported as n (%) for each response option.
Time frame: 12-15 months postoperatively
Reported as n (%) for each response option.
Time frame: 12-15 months postoperatively
Reported as median (interquartile range [IQR]) and number of respondents
Time frame: 12-15 months postoperatively
The five questions in the WOMAC pain domain can be scored 0-4, where 0 is 'none' and 4 is 'extreme'. This results in an overall score of 0-20, which will be reported as median (IQR). Moreover, each response option of the individual questions are reported as n (%).
Time frame: 12-15 months postoperatively
Reported as n (%) for each response option.
Time frame: 12-15 months postoperatively
Each of the seven questions in the DN4 interview can be scored 0/1 (no/yes), which results in an overall score of 0-7. A score ≥3 constitutes 'possible' neuropathic pain. Both the median (IQR) DN4 interview score and number of patients (% of all patients) with possible neuropathic pain will be reported.
Time frame: 12-15 months postoperatively
Pain conditions will be categorised independently by two authors and reported as n (%).
Time frame: 12-15 months postoperatively
Reported as n (%).
Time frame: 12-15 months postoperatively
Time frame: 12-15 months postoperatively
University Hospital Bispebjerg and Frederiksberg
Other
Incidence of Persistent Pain After Total Hip Arthroplasty: A Nationwide Cross-sectional Survey Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05900791
Arthritis Knee, Nervous System Diseases
Copenhagen, Denmark
View Trial DetailsNCT01320150
Neurologic Manifestations, Pain
Chicago, Illinois, United States
View Trial DetailsNCT03430765
Adenocarcinoma, Breast Cancer Female
Iowa City, Iowa, United States
View Trial DetailsNCT07693270
Chemically-Induced Disorders, Mental Disorders
La Jolla, California, United States
View Trial Details